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a systematic monitoring, as in pharmaceutical care services, seeking to promote 
safety of pharmacotherapy.
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OBJECTIVES: To study the risk of nephrotoxicity and the cost of treatment of colis-
tin. METHODS: Patients admitted in ICU with resistant bacterial infections and on 
colistin for at least seven days were included in the study. They were observed for 
any change in Glomerular filtration rate and the risk of nephrotoxicity according 
to the RIFLE criteria after the colistin therapy. The GFR values before the initiation 
of treatment with colistin were compared with that after the end of regimen. The 
pre and post treatment GFR values were compared using non-parametric Wilcoxon 
Signed Ranks test. RESULTS: A total of 30 patients on colistin were observed dur-
ing the study. The mean age of the patients was 45.47±16.45. The average APACHE 
II score was 15.87±5.82. There was no significant difference between the GFR of 
patients before and after treatment with colistin (p= 0.130). The average hospitali-
zation cost was 255245.41±138099.29 and the average cost of colistin therapy was 
31638.10±12625.90. CONCLUSIONS: This study showed that the nephrotoxic effect 
of colistin is not significant. There is a need to conduct more studies with a higher 
sample size to assess the risk of colistin-induced nephrotoxicity. The incidences 
of nephrotoxicity in the patients studied can be attributed to various other factors 
such as age, comorbidities etc. The cost of colistin therapy was substantial being 
more than one-tenth of the total hospitalization cost.
PIN3
ANIdulAfuNgIN IN cOmPArIsON tO flucONAzOle, AmPhOterIcIN 
B deOxychOlAte, AmPhOterIcIN B lIPOsOmAl, cAsPOfuNgIN ANd 
mIcAfuNgIN fOr the treAtmeNt Of INvAsIve cANdIdIAsIs AmONg NON-
NeutrOPeNIcPAtIeNts ABOve 16 yeArs: BAyesIAN mIxed treAtmeNt 
cOmPArIsON (mtc)
Diaz J.A.1, Huerfano C.1, Niño C.P.1, Alzate J.P.1, Urrego-Novoa J.R.1, Moreno J.A.2, Prieto V.A.3
1Universidad Nacional de Colombia, Bogota, Colombia, 2Salud Total EPS, Bogotá D.C., Colombia, 
3Pfizer SAS, Bogota, Colombia
OBJECTIVES: Invasive candidiasis is an important cause of complication and mor-
tality of inpatient. Anidulafungin as others echinocandins are drugs that have 
shown clinical relevance in the treatment of invasive candidiasis. This research 
sought to evaluate the effectiveness and safety of anidulafungin in comparison 
to fluconazole, amphotericin B deoxycholate, amphotericin B liposomal, caspo-
fungin and micafungin for the treatment of invasive candidiasis among non-neu-
tropenicpatients above 16 years. METHODS: We performed a systematic review 
in which were included randomized clinical trials (RCT) evaluating the different 
drugs to treatment of invasive candidiasis in non-neutropenic patients. It involved 
in MEDLINE, EMBASE, Cochrane, DARE and LILACS. The quality of evidence and risk 
of bias of clinical trials were assessed with GRADE tool and Cochrane methodol-
ogy respectively. We performed a meta-analysis and Bayesian mixed treatment 
comparison (MTC) to compare the effectiveness and safety of the different con-
sidered treatment. The outcomes of effectiveness and safetywere global response 
rate, mortality and occurrence serious event adverse (SEA). RESULTS: We included 
11 RCT and clinical evidence provided was of moderate quality according to the 
GRADE system. For global response rate, the MTC displayed that anidulafungin 
was more effective than fluconazole (OR 2.07 IC95% 1.20- 2.59). In comparison with 
others drugs, anidulafungin presented similar effectiveness (non-significant sta-
tistically differences). In mortality, it presented less proportion of events (29,5% 
IC95% 18,8-42,0) than other interventions, but it was not statistically different of 
them. Anidulafungin showed better safety profile than amphotericin B deoxycholate 
regarding to occurrence of SEA (OR 0.15 IC95% 0.02-0.97). However, there were not 
significantly statistical differences with amphotericin B liposomal, caspofungin and 
fluconazole. CONCLUSIONS: The MTC found that anidulafungin is more effective 
than fluconazole and exhibited similar effectiveness than others interventions. With 
respect to safety profile, anidulafungin was superior to amphotericin B deoxycolate 
and similar to the others.
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BACKGROUND: A landmark in the prevention of serious respiratory syncytial 
virus (RSV) infection was established with the release of palivizumab, a recom-
binant, humanized, genetically-engineered monoclonal antibody. Palivizumab 
has been deemed safe in clinical trials without major, serious adverse events 
(SAEs). OBJECTIVES: The primary objective of this study is to evaluate the safety 
and tolerability of palivizumab for RSV infection prophylaxis in high-risk chil-
dren. METHODS: High-risk children prophylaxed against RSV infection were 
recruited into a prospective, observational, Canadian RSV Evaluation Study of 
Palivizumab (CARESS) registry with active SAE monitoring from 2008 to 2013. SAE 
reports were systematically collected and assessed for severity and relationship to 
palivizumab. Data were analyzed by using Chi-square or Fisher Exact Tests to exam-
ine group differences in proportions. RESULTS: 13,025 infants were enrolled and 
received 57,392 injections: premature infants ≤ 35 weeks gestational age (n= 8224; 
63.1%), children aged < 2 years with chronic lung disease (n= 978; 7.5%), hemody-
namically significant congenital heart disease (n= 1442; 11.1%) and pre-existing 
medical disorders (n= 2381; 18.3%). 915 patients were hospitalized for a respiratory 
OBJECTIVES: To provide real-world evaluations of newer direct-acting antivirals 
(DAAs) in CHC patients from large US payer perspectives. METHODS: Medical and 
pharmacy claims linked to lab data from the Humana Database were analyzed for 
Medicare Advantage or commercially-insured adults with ≥ 2 CHC claims (ICD-9 
070.44; 070.54) who received therapy containing SMV and/or SOF through June 2014; 
those with HIV were excluded. Patients were grouped based on most common regi-
mens in the data: SMV/SOF, SMV/SOF/ribavirin (RBV), SOF/RBV, or SOF/interferon 
(IFN)/RBV; < 3% received other regimens. Baseline (BL) demographics and clinical 
characteristics (e.g., claims-based cirrhosis or end stage liver disease [ESLD], FIB-4 
scores) were described and post-treatment time measured. Methods to control for 
treatment selection bias were not performed, and comparative analyses were not 
conducted. RESULTS: There were 715 CHC patients who received therapy with SMV/
SOF (n= 184), SMV/SOF/RBV (n= 37), SOF/RBV (n= 269) or SOF/IFN/RBV (n= 225); mean 
age was between 60-62 years; 58%, 68%, 62% and 70% were male; most (85%, 78%, 
81% and 80%) had Medicare. For SMV/SOF, SMV/SOF/RBV, SOF/RBV, and SOF/IFN/
RBV groups, BL cirrhosis was present in 27%, 27%, 17%, and 24% of patients and 
ESLD in 48%, 38%, 27%, and 12% of patients, respectively. Slightly over half in each 
cohort had calculable FIB-4 scores, of which, 56%, 54%, 34% and 35%, respectively, 
had scores > 3.25. Among those with genotype data, 100% (78/78) SMV/SOF, 94.7% 
(18/19) SMV/SOF/RBV, 24.4% (29/119) SOF/RBV and 95.8% (92/96) SOF/IFN/RBV were 
genotype 1. Using prior claims history, 10%, 19%, 12% and 17% of respective cohorts 
were treatment-experienced. Less than half of each cohort had post-treatment data 
≥ 1 week. CONCLUSIONS: This analysis of CHC patients predominantly insured 
through Medicare found that the majority of those who received SMV/SOF +/- RBV 
had either cirrhosis or ESLD claims prior to therapy and, based on lab data, over 
half had FIB-4 scores > 3.25.
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OBJECTIVES: New Hepatitis C (HCV) antivirals have been shown to be highly effective 
with minimal side effects. These medications are costly and have raised significant 
concern from insurers, policymakers, advocacy groups, and patients about afford-
ability. However, little is known about the impact of new HCV antiviral expenditures. 
The objective of this study was to describe HCV antiviral expenditures by agent, 
year, and healthcare sector in the US. METHODS: HCV antiviral (interferon/ribavirin, 
telaprevir, simeprevir, sofosbuvir, boceprevir) expenditures from 10/1/2008-9/30/2014 
were obtained from the IMS Health© National Sales Perspectives database. This 
dataset represents a near-census view of US medication purchases. Expenditures 
were totaled by drug, sector, and year (defined as 10/1-9/30). Growth was calculated 
as the % increase compared to the previous year/period. RESULTS: A total of $12.2 
billion in HCV drugs were purchased from 10/2008-9/2014, 70.2% in 2014. HCV anti-
viral expenditures increased 10,880% over the six-years. Expenditures decreased by 
$7.8 million in 10/2012-9/2013 as compared to 10/2011-9/2012 (-41% growth). While 
the majority of expenditures in 10/2008-9/2010 were for interferons, this shifted to 
telaprevir in 10/2010-9/2013 and sofosbuvir in 10/2013-9/2014. Sofosbuvir was 55% of 
HCV drug expenditures over the study period and 78% in 10/2013-9/2014. By sector, 
mail order (59%) and retail (27%) pharmacies were associated with the majority of 
expenditures. CONCLUSIONS: New HCV antivirals are driving the increased expen-
ditures for this class. Decreased expenditures in 10/2012-9/2013 may have been 
secondary to delaying HCV treatment until new therapies received FDA-approval 
(“warehousing”). With continued drug development and approval of HCV therapies, 
expenditures are expected to continue to increase, barring actions by payers that 
may impede this trend. Medication policies guiding HCV treatment should focus on 
safety and efficacy while balancing the long-term costs of HCV. With the majority of 
expenditures originating from outpatient pharmacies, pharmacists are an essential 
partner to ensure appropriate use.
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OBJECTIVES: Adverse Drug Reactions (ADR) are one of the main problems related 
to antiretroviral (ARV) therapy and often result in decreased adherence and thera-
peutic failure. This study aimed to analyze the ADR that manifested during the 
Pharmacotherapeutic Monitoring (AFT) of HIV+ patients. METHODS: This was 
a longitudinal study carried out in accordance to the Dader Method of pharma-
ceutical care, which monitored 100 HIV+ patients in a center of medical spe-
cialties in Fortaleza-CE-Brazil, from November/2008 to January/2012. Data were 
collected from individual pharmacotherapeutic follow-up forms. The ADRs were 
classified according to causality as “definite, probable, possible, conditional and 
non-related” and gravity as “mild, moderate, severe and fatal”, using the World 
Health Organization (2002) method. RESULTS: Of the reported RAM (n = 267), the 
two most affected systems by ADR were the gastrointestinal tract (n = 117, ex. 
diarrhea, nausea and vomiting) and the nervous system (n= 101, ex. dizziness, 
nightmares and delusions). As for the classes of ARVs that were involved with ADR, 
the Nucleoside Reverse-Transcriptase Inhibitors (n = 113), followed by inhibitors 
non-Nucleoside Reverse-Transcriptase inhibitors (n= 73) observations and protease 
inhibitors (n = 49), were the most frequent. With regard to causality, 80.9% of RAM 
(n = 216) were classified as possible and 19.1% as probable (n = 51). As for gravity, 
85% (n = 176) were mild and 15% (n = 40) moderate. CONCLUSIONS: Data ratified 
that ARVs are triggers of ADR and its use need to be continually followed through 
